Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 5, 2010, Pages 450-455

  Uwai, Yuichi ^a   Honjo, Hiroaki ^a   Iwamoto, Kikuo ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Drug interaction; hOAT1; hOAT3; Lumiracoxib; Methotrexate; Selective cyclooxygenase 2 inhibitor; Transport

Indexed keywords

CELECOXIB; ETORICOXIB; LUMIRACOXIB; METHOTREXATE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; RNA; ROFECOXIB; VALDECOXIB;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; IC 50; NONHUMAN; OOCYTE; XENOPUS LAEVIS;

EID: 78449257506     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-048     Document Type: Article

References (19)

1. El-Sheikh, A. A., Masereeuw, R. and Russel, F. G.: Mechanisms of renal anionic drug transport. Eur. J. Pharmacol., 585: 245-255 (2008).
2. Shitara, Y., Sato, H. and Sugiyama, Y.: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol., 45: 689-723 (2005).
3. Thyss, A., Milano, G., Kubar, J., Namer, M. and Schneider, M.: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 327: 256-258 (1986).
4. Maiche, A. G.: Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet, 327: 1390 (1986).
5. Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O. and Inui, K.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13: 866-874 (2002).
6. Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Hosoyamada, M., Cha, S. H., Sekine, T. and Endou, H.: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther., 302: 666-671 (2002).
7. Uwai, Y., Taniguchi, R., Motohashi, H., Saito, H., Okuda, M. and Inui, K.: Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet., 19: 369-374 (2004).
8. Uwai, Y. and Iwamoto, K.: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: comparison with methotrexate. Drug Metab. Pharmacokinet., 25: 163-169 (2010).
9. Brouwers, J. and de Smet, P.: Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 27: 462-485 (1994).
10. Nozaki, Y., Kusuhara, H., Kondo, T., Iwaki, M., Shiroyanagi, Y., Nakayama, H., Horita, S., Nakazawa, H., Okano, T. and Sugiyama, Y.: Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther., 322: 1162-1170 (2007).
11. Maeda, A., Tsuruoka, S., Kanai, Y., Endou, H., Saito, K., Miyamaoto, E. and Fujimura, A.: Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. Eur. J. Pharmacol., 596: 166-172 (2008).
12. Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A. and Hawkey, C. J.: TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet, 364: 665-674 (2004).
13. Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Gimona, A., Matchaba, P., Hawkey, C. J. and Chesebro, J. H.: TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 364: 675-684 (2004).
14. Laine, L.,White, W. B., Rostom, A. and Hochberg, M.: COX-2 selective inhibitors in the treatment of osteoarthritis. Semin. Arthritis Rheum., 38: 165-187 (2008).
15. Rordorf, C. M., Choi, L., Marshall, P. and Mangold, J. B.: Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet., 44: 1247-1266 (2005).
16. Scott, G., Rordorf, C., Reynolds, C., Kalbag, J., Looby, M., Milosavljev, S., Weaver, M., Huff, J. P. and Ruff, D. A.: Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin. Pharmacokinet., 43: 467-478 (2004).
17. Hartmann, S. N., Rordorf, C.M., Milosavljev, S., Branson, J. M., Chales, G. H., Juvin, R. R., Lafforgue, P., Le Parc, J.M., Tavernier, C. G. and Meyer, O. C.: Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann. Pharmacother., 38: 1582-1587 (2004).
18. Tang, C., Shou, M., Rushmore, T. H., Mei, Q., Sandhu, P., Woolf, E. J., Rose, M. J., Gelmann, A., Greenberg, H. E., De Lepeleire, I., Van Hecken, A., De Schepper, P. J., Ebel, D. L., Schwartz, J. I. and Rodrigues, A. D.: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics, 11: 223-235 (2001).
19. Kirchheiner, J. and Brockmoller, J.: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 77: 1-16 (2005).